8-K: TuHURA Biosciences Secures $3.01 Million Through Warrant Exercise and Promissory Notes

TuHURA Biosciences receives $3.01 million from warrant exercises, funded by secured promissory notes bearing 12% interest.

Summary

• TuHURA Biosciences, Inc. entered into a material agreement on February 12, 2025, with four holders of common stock purchase warrants.
• These holders, referred to as the Makers, issued secured promissory notes to the Company totaling $3,011,372.60.
• This amount represents the payment for the exercise of 1,034,836 warrants.
• The Makers include KP Biotech Group, LLC, CA Patel F&F Investments, LLC, Dr. Kiran C. Patel, and Donald Wojnowski.
• Upon exercise, the Company issued 1,034,836 warrant shares to the Makers, which are considered restricted securities.
• The promissory notes carry a 12% annual interest rate, with all principal and interest due by May 30, 2025.
• The notes are secured by the warrant shares, and the interest rate increases to 18% per annum in the event of default.
• Customary events of default are defined in the notes, including nonpayment, failure to observe covenants, and bankruptcy.
• Upon an event of default, the Company can foreclose on the warrant shares or proceed against the Maker.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company secured funding, but the high interest rate and short repayment timeline introduce some risk.

Positives

• The company successfully raised $3,011,372.60 without diluting existing shareholders through a public offering.
• The funds are secured by the warrant shares, mitigating the risk of default.
• The 12% interest rate on the notes provides a return for the company if the notes are not paid by the maturity date.

Negatives

• The company is relying on a small group of investors for a significant amount of funding.
• The short-term nature of the promissory notes (due May 30, 2025) creates a near-term repayment obligation.
• An increase to an 18% interest rate upon default could indicate a higher risk associated with these notes.

Risks

• Failure of the Makers to repay the notes by the maturity date could trigger default and require foreclosure on the warrant shares.
• The value of the warrant shares securing the notes could decline, reducing the collateral's worth.
• Events of default, such as bankruptcy or insolvency of the Makers, could complicate the repayment process.
• The restricted nature of the warrant shares may limit their liquidity if the company needs to foreclose and sell them.

Future Outlook

The company anticipates receiving $3,011,372.60 by May 30, 2025, through the repayment of the promissory notes.

Industry Context

This type of financing, using warrants and promissory notes, is common for smaller biotech companies seeking to raise capital. It allows them to access funds without immediately diluting existing shareholders through a public offering.

Comparison to Industry Standards

• Comparable companies in the biotech sector often use similar financing methods, such as private placements of equity or debt, to fund research and development.
• The 12% interest rate is relatively high, suggesting a higher risk profile compared to investment-grade corporate bonds, which typically have lower interest rates.
• The use of warrant shares as collateral is a standard practice in secured lending, providing the lender with recourse in case of default.

Stakeholder Impact

• Shareholders may see a positive impact from the additional funding, but also face potential dilution if the notes default and warrant shares are issued.
• The company's ability to fund operations and research may be enhanced by the capital raise.
• Creditors may view the secured nature of the notes as a positive factor.

Next Steps

• The company needs to ensure the Makers repay the promissory notes by May 30, 2025.
• The company may need to prepare for potential foreclosure on the warrant shares if the notes are not repaid.

Key Dates